Through 2020, Generic Erosion of Blockbuster Agents Will Be a Major Contributor to a Nearly $6 Billion Decrease in the Dys

The Much-Anticipated Arrival of CETP Inhibitors is Expected to Begin in 2014 With the Launch of Roche/Japan Tobacco’s Dalcetrapib, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2020, the generic erosion of blockbuster agents—most notably Pfizer’s Lipitor, AstraZeneca/Shionogi’s Crestor, Merck’s Zetia/Ezetrol and Vytorin and Abbott’s Niaspan—will be a major contributor to a decrease of nearly $6 billion in the dyslipidemia drug market. Patent expirations will result in a decrease of approximately $19 billion in annual sales for these branded agents between 2010 and 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor advisory service entitled Dyslipidemia finds that, with sales exceeding $29 billion in 2010, dyslipidemia remains one of the largest pharmaceutical markets. The findings also reveal that the much-anticipated arrival of cholesteryl ester transfer protein (CETP) inhibitors is expected to begin in 2014 with the launch of Roche/Japan Tobacco’s dalcetrapib.

“With cardiovascular outcomes data available at launch, we expect rapid uptake of dalcetrapib, Merck’s anacetrapib and Eli Lilly’s evacetrapib as add-on therapies,” said Decision Resources Analyst Christine Helliwell, Ph.D. “The uptake of these agents will be primarily in patients who have or who are at risk of developing coronary heart disease and overall sales of CETP inhibitors will exceed $5.4 billion in 2020.”

According to the findings, the results of several major outcomes trials, including HPS2-THRIVE (for niacin-based products) and IMPROVE-IT (for Merck’s Zetia/Ezetrol), are expected to result in greater consensus among physicians regarding the choice of second- and third-line therapies and will trigger changes in international guidelines for dyslipidemia management.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.